The drug Healix, manufactured by Wellco, is used to treat Roth’s syndrome. Wellco claims Healix is a far better protocol for the treatment of Roth’s than Painfre, a drug manufactured by Pharmco. In fact, Wellco claims that 50 percent of patients who suffer from Roth’s get positive results as compared with 20 percent who are treated with Painfre. Pharmco claims Wellco’s assertion of superiority is misleading because, in patients who have liver failure, a common complication of Roth’s, Painfre is more effective than Healix.
Which of the following statements would support Pharmco’s claim?
A. Healix is a drug that must be metabolized by the liver to become active.
B. Drug trials conducted on Roth’s syndrome patients comparing Helix to a placebo showed a positive response in 50 percent to 55 percent of the patients.
C. Drug trials of Painfre were conducted by pharmacological researchers employed by Pharmco.
D. Biotechnical research conducted by Wellco was funded by a consortium of physicians who treat patients with liver failure.
E. The drug trials of Healix were conducted in a double-blind procedure, which is used to guard against experimenter and subject bias.